M. Manning

发表

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial

William H. Yang, J. Bernstein, W. Lumry, 2018, JAMA.

Treatment patterns and healthcare resource utilization among patients with hereditary angioedema in the United States

T. Machnig, N. Joshi, M. Riedl, 2018, Orphanet Journal of Rare Diseases.

Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema.

J. Bernstein, W. Lumry, J. Schranz, 2014, The journal of allergy and clinical immunology. In practice.

Aspirin sensitivity. A distressing reaction that is now often treatable.

D. Stevenson, M. Manning, D. D. Stevenson, 1991, Postgraduate medicine.

Pseudoallergic drug reactions : aspirin, nonsteroidal antiinflammatory drugs, dyes, additives, and preservatives

M. Manning, D. D. Stevenso, 1991 .

A study to assess current approaches of allergists in European countries diagnosing and managing children and adolescents with peanut allergy

Vibha Sharma, S. Tilles, M. Manning, 2020, PloS one.

Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma.

S. Wenzel, W. Lumry, F. Cox, 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Pseudoallergic Drug Reactions

D. Stevenson, M. Manning, 1991, Immunology and Allergy Clinics of North America.

Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children.

W. Lumry, M. Davis-Lorton, M. Manning, 2013, The Journal of pediatrics.

Nano fi ltered C 1-Esterase Inhibitor for the Acute Management and Prevention of Hereditary Angioedema Attacks due to C 1-Inhibitor De fi ciency in Children

W. Lumry, M. Davis-Lorton, M. Manning, 2013 .

Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema.

J. Bernstein, W. Lumry, P. Busse, 2010, The New England journal of medicine.

Recognition and Management of Hereditary Angioedema: Best Practices for Dermatologists

M. Manning, 2021, Dermatology and Therapy.

Long-Term Efficacy of Subcutaneous C1 Inhibitor in Pediatric Patients with Hereditary Angioedema

I. Hussain, M. Cicardi, I. Pragst, 2018, Pediatric allergy, immunology, and pulmonology.

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

William H. Yang, P. Keith, P. Kralickova, 2017, The New England journal of medicine.

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

P. Keith, T. Machnig, J. Bernstein, 2021, Orphanet Journal of Rare Diseases.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

P. Keith, T. Machnig, J. Bernstein, 2018, The journal of allergy and clinical immunology. In practice.

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

M. Triggiani, J. Bernstein, M. Gompels, 2018, Allergy.

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

William H. Yang, J. Bernstein, W. Lumry, 2023, The Lancet.

Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: additional outcomes and subgroup analysis of a placebo-controlled randomized study

T. Machnig, J. Bernstein, W. Lumry, 2019, Allergy, Asthma & Clinical Immunology.

Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.

T. Machnig, J. Bernstein, W. Lumry, 2019, The journal of allergy and clinical immunology. In practice.

Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks

T. Machnig, J. Bernstein, G. Krishnarajah, 2019, Allergy, Asthma & Clinical Immunology.

Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Subcutaneous (SC) Cinryze® (C1 inhibitor (C1 INH) with Recombinant Human Hyaluronidase (rHuPH20) in Subjects with Hereditary Angioedema (HAE)

S. Dychter, W. Lumry, S. Gelone, 2012 .

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

P. Keith, T. Machnig, J. Bernstein, 2021, Orphanet Journal of Rare Diseases.

Intravenous C1-INH [C1-INH(IV)] Use Among Patients with Hereditary Angioedema (HAE) in the United States (US) and Associated Health Care Resource Utilization (HCRU)

T. Machnig, N. Joshi, M. Riedl, 2017 .

Berotralstat (BCX7353) is a novel oral prophylactic treatment for hereditary angioedema: Review of phase II and III studies.

M. Manning, J. Kashkin, 2021, Allergy and asthma proceedings.

Inhibition of Prekallikrein for Hereditary Angioedema.

J. Bernstein, W. Lumry, B. Baker, 2022, The New England journal of medicine.

Efficacy and Safety of Long-Term Prophylaxis with C1 Inhibitor (C1INH) Concentrate in Patients with Hereditary Angioedema (HAE)

W. Lumry, P. Busse, D. Tanner, 2008 .

Hereditary angioedema: Differential diagnosis, diagnostic tests, and family screening.

M. Manning, 2020, Allergy and asthma proceedings.

Subcutaneous Immunoglobulin 16.5% (Cutaquig®) in Primary Immunodeficiency Disease: Safety, Tolerability, Efficacy, and Patient Experience with Enhanced Infusion Regimens

R. Kobayashi, J. Walter, J. Bernstein, 2023, Journal of Clinical Immunology.

Efficacy And Safety Of Bradykinin B2 Receptor Inhibition With Oral PHVS416 In Treating Hereditary Angioedema Attacks: Results Of RAPIDe-1 Phase 2 Trial

William H. Yang, P. Kralickova, R. Crabbé, 2023, Journal of Allergy and Clinical Immunology.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

Patient outcomes associated with subcutaneous C1INH prophylaxis for hereditary angioedema: a retrospective analysis

W. Lumry, R. Tachdjian, M. Riedl, 2023, Allergy, Asthma & Clinical Immunology.

A phase 2 open‐label extension study of prekallikrein inhibition with donidalorsen for hereditary angioedema

W. Lumry, R. Tachdjian, M. Riedl, 2023, Allergy.